Onkologie. 2010:4(3):181-184

Bevacizumab: current status of malignant tumors treatment

Jiří Tomášek, Štěpán Tuček
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

Angiogenesis is a key process in growth and metastatic spread of malignant tumors. Enthusiastic research over past years has produced

several therapeutic agents targeting angiogenesis, available in clinical practice. The most advanced in the treatment of solid tumors

at present time is bevacizumab, a humanized monoclonal anti-VEGF antibody. It has become a part of standard treatment of metastatic

colorectal cancer and is settling in the treatment of breast, kidney and lung cancers. To determine the role of bevacizumab in the

treatment of other solid malignancies, there are many clinical trials ongoing. The toxicity profile has been well described and is quite

favorable. The article brings a basic overview of the clinical use of bevacizumab based on clinical studies.

Keywords: angiogenesis, bevacizumab, VEGF, solid tumors

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomášek J, Tuček Š. Bevacizumab: current status of malignant tumors treatment. Onkologie. 2010;4(3):181-184.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23(5): 1011-1027. Go to original source... Go to PubMed...
    2. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300(19): 2277-2285. Go to original source... Go to PubMed...
    3. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-smallcelllung cancer. J Clin Oncol 2004; 22(11): 2184-2191. Go to original source... Go to PubMed...
    4. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65. Go to original source... Go to PubMed...
    5. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long - term safety data. J Clin Oncol 2001; 19: 851-856. Go to original source... Go to PubMed...
    6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. Go to original source... Go to PubMed...
    7. Fuchs CS, Marshall J, Barrueco J, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2007; 25(30): 4779-4786. Go to original source... Go to PubMed...
    8. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12): 2013-2019. Go to original source... Go to PubMed...
    9. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26(33): 5326-5334. Go to original source... Go to PubMed...
    10. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Annals of Oncology 2009. Go to original source...
    11. Prausová, et al. Safety and effectiveness of bevacizumab in combination with chemotherapy in patients with metastatic colorectal cancer: updated results from a large Czech Observational Registry, WCGC Barcelona 2009, P-0171.
    12. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27(20): 3385-3390. Go to original source... Go to PubMed...
    13. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-2676. Go to original source... Go to PubMed...
    14. Gray R, Bhattacharya S, Bowden Ch, et al. Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer. J Clin Oncol 2009; 27(30): 4966-4972. Go to original source... Go to PubMed...
    15. Milec DW, Chan A, Dirix LY, et al. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2010. Go to original source... Go to PubMed...
    16. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebocontrolled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstractLBA1011]. American Society of Clinical Oncology (ASCO) Annual Meeting 2008; Chicago (IL). Go to original source...
    17. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapywith orwithout bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract 1005]. J Clin Oncol 2009; 27(15 Suppl.): 42. Go to original source...
    18. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103-2111. Go to original source... Go to PubMed...
    19. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26(33): 5422-5428. Go to original source... Go to PubMed...
    20. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone orwith bevacizumab for non-small-cell lung cancer. NEngl JMed 2006; 355(24): 2542-2550. Go to original source... Go to PubMed...
    21. Reck M, Von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27(8): 1227-1234. Go to original source... Go to PubMed...
    22. Prausová, et al. Safety and effectiveness of bevacizumab in combination with chemotherapy in patients with metastatic colorectal cancer: updated results from a large Czech Observational Registry, WCGC Barcelona 2009, P-0171.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.